Table 2.
VR, CR, HBeAg seroconversion and HBsAg loss in patients after NAs cessation
| 3 months (%) | 6 months (%) | 9 months (%) | 12 months (%) | 15 months (%) | 18 months (%) | 21 month (%) | 24 month (%) | In total (%) | |
|---|---|---|---|---|---|---|---|---|---|
| VR | 9 (6.5) | 21 (21.6) | 15 (32.4) | 9 (38.8) | 5 (42.4) | 4 (45.3) | 2 (46.8) | 5 (50.4) | 70 (50.4) |
| CR | 2 (1.4) | 6 (5.8) | 9 (12.2) | 4 (15.1) | 5 (18.7) | 5 (22.3) | 3 (24.5) | 0 (24.5) | 34 (24.5) |
| HBeAg reversion | 1 (1) | 6 (5) | 3 (7.2) | 2 (8.6) | 1 (9.4) | 1 (10.1) | 0 (10.1) | 2 (11.5) | 16 (11.5) |
| HBsAg loss | 2 (1.4) | 2 (2.9) | 0 (2.9) | 2 (4.3) | 2 (5.8) | 1 (6.5) | 1 (7.2) | 3 (9.4) | 13 (9.4) |
The data are expressed as number of new cases per visit (cumulative incidence)
VR virological relapse, CR clinical relapse